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ABSTRACT
Background. Immunosuppressed patients such as kidney transplant recipients (KTs) have increased mortality risk in the
setting of coronavirus disease 2019 (COVID-19). The role and management of chronic immunosuppressive therapies during
COVID-19 must be characterized.
Methods. Herein, we report the follow-up of a cohort of 47 KTs admitted at two Spanish Kidney Transplant Units, who
survived COVID-19. The impact of the management of immunosuppression during COVID-19 on graft function and
immunologic events was evaluated.
Results. At least one immunosuppressive agent was withdrawn in 83% of patients, with antimetabolites being the most frequent.
Steroids were generally not stopped and the dose was even increased in 15% of patients as part of the treatment of COVID-19.
Although immunosuppressive drugs were suspended during a median time of 17 days, no rejection episodes or de novo donor-
specific antibodies were observed up to 3 months after discharge, and no significant changes occurred in calculated panel
reactive antibodies. Acute graft dysfunction was common (55%) and the severity was related to tacrolimus trough levels, which
were higher in patients receiving antivirals. At the end of follow-up, all patients recovered baseline kidney function.
Conclusions. Our observational study suggests that immunosuppression in KTs hospitalized due to COVID-19 could be safely
minimized.
Keywords: acute kidney injury, allograft rejection, coronavirus disease 2019, donor-specific antibodies, immunosuppres-
sion, kidney transplantation
INTRODUCTION
Immunosuppressed patients, in particular solid-organ trans-
plant recipients (SOTs), have an increased risk of viral and
bacterial infections as a consequence of diminished T-cell
immunity. In the early days of the current pandemic, it was sug-
gested that kidney transplant recipients (KTs) could have severe
manifestations of coronavirus disease 2019 (COVID-19) due, at
least in part, to chronic immunosuppressive therapy [1–3]. More
recently, several studies have confirmed a substantially worse
prognosis in this population [4], with a large European cohort
reporting a mortality risk 92 times higher in KTs with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infec-
tion as compared with their uninfected counterparts and a 28%
greater risk compared with dialysis patients [5].
Spain was one of the most affected countries during the first
wave of the COVID-19 pandemic, and transplant units coped
with a significant number of infected and hospitalized KTs
without evidence-based strategies concerning therapeutic man-
agement [6]. It has been proposed that management of viral
infections after solid-organ transplantation should include anti-
viral drug therapies and immunosuppression reduction, since
progression to severe disease has been correlated with overim-
munosuppression. Consequently, a reduction of immunosup-
pressive agents appears as a rational strategy to allow the
development of specific immunity [7]. In fact, an expert consen-
sus document suggests a progressive withdrawal of immuno-
suppression depending on the severity of the disease [8], and
previous works have already described the withdrawal of at
least one immunosuppressive drug in KTs with COVID-19, and
this strategy does not seem to have an impact on patient sur-
vival [1–3, 6]. On the contrary, KTs with COVID-19 present lower
CD3, CD4 and CD8 cell counts than the general population,
which further supports an immunosuppression minimization
approach for the management of the infection [2]. Despite the
overwhelming number of current publications on COVID-19 and
kidney transplantation, there is scarce information on the evo-
lution of alloimmune humoral response after reduction of im-
munosuppression in KTs hospitalized due to SARS-CoV-2
infection. Moreover, to the best of our knowledge, no data on
the evolution of kidney graft function in COVID-19 survivors
has been reported. This is of special relevance given that acute
kidney injury (AKI) has been frequently described among KTs
with COVID-19 [9, 10].
Herein, we report 3-month follow-up of 47 KTs who survived
COVID-19 in two Spanish Kidney Transplant Units. We aimed
to evaluate the impact of immunosuppression reduction/
withdrawal during the course of COVID-19 on kidney graft
function and to assess the influence of immunosuppression
reduction/withdrawal on the possible appearance of de novo




This is a two-centre observational study. All COVID-19-positive
KTs hospitalized between 12 March and 29 June 2020 were in-
cluded. COVID-19 diagnosis was confirmed by positive results
on real-time reverse transcriptase–polymerase chain reaction
(RT-PCR) on nasal and/or pharyngeal swab samples. Swab tests
were not available in four patients. In the latter cases, a pre-
sumptive diagnosis was made based on computed tomography
scan or chest X-ray findings and compatible clinical presenta-
tion. Hospitalization criteria included need for oxygen therapy,
radiographic evidence of pulmonary infiltrates, kidney graft
dysfunction and recent onset of symptoms (<7 days).
Therapies for COVID-19 were quite homogeneous among the
two institutions and varied according to the new data that have
become known over time. Immunosuppression management
was based on antimetabolite [mycophenolate mofetil (MMF)/
mycophenolic acid (MPA)] withdrawal at admission or in some
cases only when lymphopaenia was present and was later rein-
troduced when total lymphocyte counts improved or according
to the physician’s discretion. Tacrolimus (TAC) or mammalian
target of rapamycin inhibitors (mTORi) interruption was
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reserved for extremely severe cases [intensive care unit (ICU)
admission, acute respiratory distress syndrome].
We analysed data from patients who were discharged after
COVID-19 and had follow-up data available at 3 months after
discharge. KTs with an estimated glomerular filtration rate
(eGFR) 15 mL/min/1.73 m2 as measured by the Chronic Kidney
Disease Epidemiology Collaboration equation and patients who
did not survive COVID-19 were excluded from the analysis.
Serum creatinine (SCr), eGFR, proteinuria, microhaematuria,
lymphopaenia and TAC trough levels were retrospectively
collected at 3 and 6 months before admission, at hospital admit-
tance and at discharge. Then, we prospectively measured the
aforementioned variables at 3 months after discharge. AKI was
defined according to the Kidney Disease: Improving Global
Outcomes classification [11].
Measurements of human leukocyte antigen (HLA) Class I (A, B)
and Class II (DR, DQ), of both the recipient and the donor, were
performed by DNA-based low-resolution typing with sequence-
specific primers. All samples were tested by single-antigen bead
assay (SAB; One Lambda) to detect donor-specific anti-HLA IgG by
single-antigen Classes I and II flow beads assay kit. The test was
considered positive if mean fluorescence intensity (MFI) was >500
or if MFI/MFI lowest bead was >5. In the presence of DSA, the
missing alleles were inferred from their haplotype associations
with HaploStats [12]. Pre-COVID-19 SAB tests were performed be-
tween 6 and 12 months before admission, while post-COVID-19
SAB tests were performed 3 months after discharge.
This study was conducted in accordance with the amended
declaration of Helsinki and was approved by the hospital ethical
review boards (PR230/20).
Statistical analysis
Continuous variables were expressed as mean 6 standard devi-
ation or median and interquartile range (IQR) and categorical
variables as total number (n) and percentage (%). Comparison
between groups was performed using Pearson’s v2 test for cate-
gorical data and Fisher’s exact test was applied when the num-
ber of cases was fewer than five. One-way analysis of variance
and t-tests were used for normally continuous distributed data,
and nonparametric Kruskal–Wallis test and Mann–Whitney U-
test for non-normally distributed variables. P-values were two-
tailed and statistical significance level was established at
P< 0.05. SPSS 20.0 software (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA,
USA) were used for data management and analysis.
RESULTS
During the observation period, 74 patients were admitted to our
institutions due to SARS-CoV-2 infection. Twenty-four of them died
and were excluded from the analysis. Additionally, three patients
with baseline eGFR15 mL/min/1.73 m2 who started haemodialysis
during admission were ruled out, since immunosuppression with-
drawal was carried out as part of a protocol after kidney graft fail-
ure and kidney function recovery was not expected (Figure 1).
Ultimately, 47 patients were suitable for the final analysis.
Five out of 47 (10.6%) patients required ICU management
and 4/47 (8.5%) invasive mechanical ventilation. Baseline (pre-
admission) eGFR was 46 mL/min/1.73 m2 (mean of two deter-
minations) and proteinuria was minimal. The main clinical
characteristics of the study population are detailed in Table 1.
Regarding immunological features, most patients had baseline
cPRA of 0%, four patients (8.5%) had known DSA before
admission and six (12.7%) had a history of rejection episodes
(one humoral and five cellulars). Median time from kidney
transplantation to COVID-19 diagnosis was 109 months.
74 kidney transplant recipients
hospitalized due to COVID-19
between 12 March and 29 June, 2020
(HUB: 39; 12 October: 35)
Follow-up and analysis of
47 kidney transplant recipients
after 3 months of COVID-19
Excluded from the analysis:
• 24 died
• 3 with eGFR ≤ 15 mL/min 
FIGURE 1: Flow chart of the study. Only subjects who required hospital admis-
sion were included.
Table 1. Baseline clinical characteristics of the study population
Sex (male/female), n (%) 18/29 (39/61)
Age at COVID-19 diagnosis (years), mean 6 SD 59 6 12
Ethnicity (Caucasian/other), n (%) 40/7 (85/15)
Type of donor (deceased/living), n (%) 41/6 (87/13)
Number of transplants (1/>1), n (%) 40/7 (85/15)




Heart disease (Y/N), n (%) 11/36 (23.4/76.6)
Pulmonary disease (Y/N), n (%) 7/40 (14.9/85.)
Hypertension (Y/N), n (%) 4/43 (8.5/91.5)
Diabetes mellitus (Y/N), n (%) 13/34 (27.7/72.3)
Obesity (BMI >30 kg/m2 Y/N), n (%) 14/33 (29.8/70.2)
RAASi, n (%)
None 28 (59.6)
ACE inhibitors 13 (27.7)
Angiotensin receptors blockers 6 (12.8)
Anticoagulation treatment (Y/N), n (%) 8/39 (17/83)
Time from transplantation to
COVID-19 diagnosis (months), IQR
109 (30–191)
cPRA %, median (IQR) 0 (0–18)
cPRA >90 (%) 5 (10.6)
DSA Class I 3 (6.4)
DSA Class II 1 (2.1)
DSA Classes I and II 4 (8.5)
Previous rejection episode
All (n %) 6 (12.8)
Cellular (%) 5 (10.6)
Humoral (%) 1 (2.1)








Urinary protein creatinine ratio (g/mol),
median (IQR)
16.5 (9–34.4)
aThree patients were excluded because kidney function was not stable due to
recent transplantation (<6 months).
BMI, body mass index; RAASi, renin–angiotensin–aldosterone system inhibitors;
ACE, angiotensin-converting enzyme.
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Immunosuppression management before, during and
after COVID-19
Most patients were taking calcineurin inhibitors (CNI)-based im-
munosuppression, mainly accompanied by antimetabolites,
and 68% were on steroids. During admission, withdrawal of at
least one immunosuppressive drug was common (83%), while
total immunosuppression withdrawal was performed in 17% of
cases. The percentage of withdrawal for each immunosuppres-
sive agent and the length of withdrawal (days) is presented in
Table 2. Patients with MMF/MPA withdrawal had more severe
lymphopaenia during hospital stay (median lymphocyte nadir
during admission 720 6 387 versus 451 6 216, P¼ 0.02) and dura-
tion of immunosuppression withdrawal was longer for antime-
tabolites as compared with other drugs. Of note, 15% of patients
received high-dose intravenous steroids. Figure 2 displays the
immunosuppression reduction strategy for each patient of the
cohort.
Graft function evolution
During a median hospital stay of 14 days (IQR 9–25), 26 (55%)
patients developed AKI; 18 (38%) cases Stage I, 4 cases Stage II
(8.5%) and 2 cases (4.2%) Stage III. One AKI episode was of
obstructive nature due to anastomotic ureteral stricture in a
patient transplanted 3 months before admission. The empiri-
cal treatment for COVID-19 used during the first wave of the
pandemic according to AKI status during hospitalization is
shown in Figure 3. Notably, more AKI episodes were observed
in patients receiving antivirals (except for remdesivir); how-
ever, this was not significant (32% versus 19%, respectively,
P¼ 0.3). Not surprisingly, the use of antivirals had a strong re-
lationship with high TAC trough levels, as can be seen in
Figure 4. Median TAC trough levels were higher in patients
receiving such drugs compared with no antiviral therapy [9
(IQR 8.1–10.9) versus 35.6 (IQR 14.6–44), P¼ 0.009]. Consequently,
patients who received antivirals had higher rates of TAC with-
drawal (54% versus 18%, P¼ 0.03). Of interest, AKI was not
associated with the use of renin–angiotensin–aldosterone system
Table 2. Baseline immunosuppression and management during
COVID-19












Follow-up (months), median (IQR) 4 (3–5)
Any IMS withdrawal (Y/N) 38/9 (80.9/19.1)
All IMS withdrawal (Y/N) 8/39 (17/83)
TAC withdrawala (Y/N) 10/27 (27/73)
Day TAC withdrawal, median (IQR) 13 (5–21)
Antimetabolite withdrawal (n ¼ 36) (Y/N) 31/5 (86/14)
Day antimetabolite withdrawal, median (IQR) 20 (11–31)
mTORi withdrawal (n ¼ 14) (Y/N) 8/6 (57/42)
Day mTORi withdrawal, median (IQR) 15 (4–21)






































FIGURE 2: Management of immunosuppression. Each line corresponds to a pa-








































































































FIGURE 3: Treatment for COVID-19 (distribution according to AKI during hospi-
talization). *Except remdesivir.
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inhibitors before admission (56% versus 44%, P¼ 0.68). On the
contrary, the severity of AKI was related to TAC trough levels
[TAC trough levels 9.1 (IQR 6.9–12.6) for no AKI, TAC trough levels
9.4 (IQR 8.2–29) for AKI I, TAC trough levels 26 (IQR 15–45) for AKI
II–III, P¼ 0.026; Figure 5]. Globally, 23.4% of patients had TAC
trough levels >20mg/L, with all cases returning to baseline levels
at 3 months after discharge [median TAC trough levels of 10.2 lg/
L (IQR 8.6–19.9) at admission; median TAC trough levels of 6.1lg/L
(IQR 5.2–7.8) at 3 months]. Proteinuria did not exhibit relevant
changes before and after COVID-19 (D 0.6 6 4 g/mol). Finally, all
patients with AKI recovered baseline kidney graft function as
shown by SCr evolution in Figure 6. One patient who did not de-
velop AKI during admission experienced an AKI episode 3 months
after COVID-19, but in the context of an acute graft pyelonephri-
tis. No patient developed de novo DSA at 90 days after discharge.
The MFI levels before and after COVID-19 for patients with
known DSA previous to admission are presented in Figure 7. One
patient exhibited an important reduction of MFI DSA against
Class I, while a low MFI titre DSA against Class II disappeared,
and cPRA decreased from 64% to 18%. Notably, this patient did
not undergo immunosuppression reduction as COVID-19 clinical
presentation was mild. Overall, cPRA remained unchanged in
most patients, with the exception of two cases where cPRA in-
creased from 0% to 1% and 18%, respectively, whereas cPRA re-
duction was observed in two patients (one previously mentioned













































FIGURE 6: SCr evolution at different time points (3 and 6 months before admis-















































FIGURE 4: Use of antiviral drugs (excluding remdesivir) and tacrolimus trough





































































































FIGURE 8: Evolution of cPRAs before and after COVID-19.
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DISCUSSION
In this study, we have found that an immunosuppressive
minimization strategy in KTs with COVID-19 appears safe as no
rejection episodes or appearance of de novo DSA or relevant
changes in cPRA at 90 days after discharge were observed. KTs
are susceptible to severe manifestations of COVID-19 due to
their immunosuppressive status [2, 3]. Maggiore et al., on behalf
of the DESCARTES Working Group of the ERA-EDTA, proposed a
progressive approach of immunosuppression withdrawal
depending on the severity of SARS-CoV-2 infection [8]. It is im-
portant to note that the latter recommendation is based on ex-
pert opinion, and no previous study has analysed the impact of
such strategy. However, since the immune response to infec-
tions is reduced in immunosuppressed patients, such as KTs, it
seems rational to temporarily reduce or withdraw immunosup-
pression. In fact, the vast majority of published studies regard-
ing KTs management and outcomes in the setting of COVID-19
have reported performing some kind of immunosuppression
minimization [13]. Interestingly, a recent large multicentre in-
ternational observational study by the TANGO International
Transplant Consortium found no significant association be-
tween withdrawal of immunosuppression and mortality in KTs
with COVID-19 [9].
In our study population, most patients had at least one im-
munosuppressive agent withdrawn, with the exception of ste-
roids. A recent systematic review by Marinaki et al. [14],
including 420 KTs with COVID-19, reported that reduction/with-
drawal of immunosuppression was done in 58% patients and all
immunosuppressive agents were maintained in only 5%. In our
case, 80.9% of patients were managed with immunosuppression
reduction, while 19.1% maintained the complete immunosup-
pressive regimen (Table 2). CNI and mTORi were stopped
depending on the severity of the disease, with an observed re-
duction rate of 27% and 57%, respectively. This is in line
with the work by Marinaki et al., where similar reduction rates
(32% and 58%, respectively) were described. Also, the drug
that was most commonly withdrawn was MMF (91%), similar
to our study where MMF/MPA represented 86% of the cases. Of
note, in some cases, the interruption of antimetabolites in our
cohort was reactive to the degree of lymphopaenia, which could
account for the longer withdrawal time of antimetabolites as
compared with other immunosuppressive agents. Another ret-
rospective study including 773 SOTs with COVID-19 found a sig-
nificant association between antimetabolite withdrawal and
better survival; however, no data on alloimmune response or
longer follow-up were provided [15]. In spite of immunosup-
pression minimization, none of our patients developed de novo
DSA or acute rejection episodes after a median time of 4 months
after COVID-19 hospitalization. Moreover, one hypersensitized
patient with DSA before COVID-19 (who did not experience im-
munosuppression withdrawal) presented a notable reduction in
MFI of DSA. These observations suggest that SARS-CoV-2 infec-
tion probably decreases immunity to a great extent, including
alloimmune response. Nonetheless, Akilesh et al. [16] recently
reported two cases of humoral rejection in KTs with COVID-19.
One patient had histological features of chronic humoral rejec-
tion, while the other presented microangiopathy lesions. In
both cases, the biopsy was performed on a deferred basis (graft
dysfunction was present at the time of admission) and the
patients had a previous history of rejection and DSA.
Considering this, in our opinion, the possibility of SARS-CoV-2
infection as a trigger for the development of rejection remains
purely speculative. In fact, our data suggest that withdrawal of
immunosuppressants in the course of illness and their later
reintroduction is safe in KTs. Furthermore, since dexametha-
sone at high doses is currently recommended for the treatment
of moderate–severe COVID-19 [17], withdrawal
of antimetabolites or other immunosuppressive agents is
probably advisable to prevent complications associated with
overimmuno-suppression.
AKI is a well-known complication of COVID-19 and its pres-
ence has been associated with higher mortality risk. Patients
needing kidney replacement therapy (KRT) and patients with
chronic kidney disease (CKD) had the lowest probability of re-
covering kidney function [18, 19]. In addition, AKI incidence in
KTs with COVID-19 is high, with most studies reporting an inci-
dence of nearly 50% [6, 9]. To date, the pathophysiology of
COVID-19-associated AKI has not been clearly established.
Proposed mechanisms include decreased kidney perfusion, vi-
ral cytopathic effect, coagulation dysfunction and microangiop-
athy. Also, interaction of different drugs leading to CNI
nephrotoxicity in KTs is another possible mechanism [6]. In our
study, the severity of AKI was closely related to TAC trough lev-
els, and these were higher in patients taking antivirals treat-
ment. It is worth noting that some of these treatments are no
longer recommended for COVID-19 management, such as the
case of ritonavir/lopinavir. These drugs interact strongly with
CYP3A4 and might cause a marked increase of TAC levels, lead-
ing to a higher rate of kidney dysfunction. In general, TAC
trough levels during hospitalization in our study population
were higher when compared with pre-admission levels, sug-
gesting that other factors such as diarrhoea and/or change in
volume distribution could be related to CNI nephrotoxicity.
Interestingly, all patients recovered baseline kidney function at
3 months after discharge, including the few patients with more
severe AKI. These data contrast with studies by Ng et al. [19] and
Gupta et al. [20], in which 30–34% of patients with AKI remained
dialysis-dependent at discharge. This discrepancy could be
explained by several factors, including the low prevalence of se-
vere AKI in our cohort, the relatively good eGFR before admis-
sion and the exclusion of patients with eGFR inferior to 15 mL/
min/1.73 m2. Besides, most patients admitted at our centres
that required ICU management and KRT did not survive, and
therefore were also excluded from the analysis. This is in line
with the high mortality reported for SOTs requiring ICU admis-
sion [15].
Our study has several limitations. The follow-up period was
relatively short. Nonetheless, a longer follow-up time would
probably not alter the results since immunosuppression was
reintroduced in all patients. Secondly, due to the low-resolution
HLA typification we have employed, we had to infer the allele of
DSA using the HaploStats program to minimize the possibility
of errors in some cases. Thirdly, time from transplantation in
our cohort was significantly higher than that reported in other
studies, thus, our results may not be applicable to recent KTs.
Finally, the small sample size of our study precludes establish-
ing definitive associations.
In conclusion, our study has found that temporary with-
drawal of immunosuppressive treatments in KTs with COVID-
19 appears to be safe, since no patients experienced rejection
episodes or developed de novo DSA. Additionally, most of AKI
events in our cohort were probably due to CNI nephrotoxicity
rather than directly associated with COVID-19. At the end
of follow-up, all patients with AKI who survived recovered
baseline graft function.
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